Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS,Neuropathology and Applied Neurobiology

当前位置： X-MOL 学术 › Neuropathol. Appl. Neurobiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS
Neuropathology and Applied Neurobiology ( IF 5 ) Pub Date : 2023-06-15 , DOI: 10.1111/nan.12919
Yue Yang _{1,

2} , Dominic Rowe ₃ , Heather McCann ₄ , Claire E Shepherd ₄ , Jillian J Kril _{2,

5} , Matthew C Kiernan _{1,

6} , Glenda M Halliday _{1,

2} , Rachel H Tan _{1,

2}

Affiliation

Although the orally available brain-penetrant copper compound CuATSM has demonstrated promising effects in SOD1-linked mouse models, the impact of CuATSM on disease pathology in patients with amyotrophic lateral sclerosis (ALS) remains unknown.

中文翻译：